By Sheeba M. | Weedstock Market Intelligence | Thursday, October 1, 2026
As cannabis markets work through Thursday’s midday session, institutional attention is locked onto two of the sector’s largest multi-state operators: Curaleaf (CURLF) and Verano Holdings (VRNOF). With Q3 2026 earnings season approaching and the DEA rescheduling timeline still unresolved, analysts are running dual-scenario models — base case steady-state and bull case 280E relief — for both names entering Q4.
Curaleaf CURLF: International Optionality Meets Domestic Discipline
Curaleaf enters Q4 with a leaner operational footprint following its 2025 retail consolidation. After closing underperforming dispensaries in several Northeast markets, the company reallocated capital toward its European cannabis platform — one of the few genuine international revenue streams among U.S.-listed MSOs. Q3 revenue consensus for CURLF sits in the $310–325M range, with adjusted EBITDA margins expected to hold near 22–24%.
The 280E overhang remains the dominant valuation variable. Curaleaf carries approximately $600M in long-term debt, and management has guided toward refinancing at improved terms contingent on rescheduling clarity. The stock currently trades at a significant 280E-adjusted discount to trailing cash flows — a gap that closes dramatically under any federal tax relief scenario. Track live CURLF price and news flow on the Weedstock tracker.
Verano VRNOF: Margin Defense in Limited-License States
Verano’s midday positioning reinforces its identity as the margin-discipline story within large-cap cannabis. Concentration in limited-license states — Illinois, New Jersey, Florida, and Pennsylvania — insulates VRNOF from the worst retail pricing pressure seen in mature markets like Colorado and Oregon. Q3 estimates project revenue near $215–230M with EBITDA margins pushing toward 30%, among the highest in the sector.
Management’s capex freeze strategy, announced in late 2025, has converted to stronger free cash flow generation throughout 2026. That FCF story becomes significantly more compelling under 280E relief, where effective tax rates drop sharply for profitable operators. Florida remains the most watched single-state exposure: the medical market has held firm despite the failed 2024 recreational ballot measure, and Verano’s vertical integration provides a durable cost advantage over smaller in-state competitors. Follow VRNOF on the cannabis tracker for intraday updates.
280E Relief: The Q4 Earnings Multiplier
Section 280E of the Internal Revenue Code prohibits standard business deductions for entities trafficking Schedule I or II controlled substances — effectively imposing a 20–40% drag on net income for profitable MSOs. Any federal rescheduling decision eliminating or reducing 280E liability represents an earnings multiple expansion event, not merely a tax savings. Sell-side models for CURLF show earnings power potentially doubling on a trailing basis under a full 280E relief scenario; VRNOF, with stronger underlying margins, would see a proportionally meaningful improvement as well.
Both names report Q3 results in November. Pre-earnings, cannabis stocks typically experience elevated volatility around DEA-related headlines, state legislative calendars, and federal committee activity. Weedstock’s real-time cannabis stock tracker monitors CURLF, VRNOF, and the full MSO universe for price, volume, and news flow throughout every session.
This article is for informational purposes only and does not constitute investment advice. Cannabis investments carry substantial risk. Always consult a qualified financial advisor before investing.